Latest Multiple Myeloma Research Consortium Stories
SAN FRANCISCO (Reuters) - Celgene Corp. said on Monday that a pivotal-stage trial of its Thalomid drug was stopped early after the medicine was shown to dramatically limit the progress of the blood cancer multiple myeloma. The drug, also known as thalidomide, was first introduced in the 1950s and became notorious for causing birth defects. It is currently approved for treating a symptom of leprosy. The Phase 3 trial of 270 patients found that that it took an average of 75.7 weeks for...
- The offense of persistently instigating lawsuits, typically groundless ones.
- An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
- Sale or purchase of positions in church or state.